---
title: "Damora Q2 net loss widens to $31.17 million"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295443352.md"
description: "Damora Therapeutics reported a widened GAAP net loss of $31.17 million for Q2 2026, up from $3.44 million in the prior year. Operating losses increased to $34.99 million due to surging R&D and G&A expenses. However, other income improved to $4.08 million driven by higher interest income. The company also initiated a Phase 1/1b trial for its lead candidate DMR-001, with proof-of-concept readouts expected mid-2027."
datetime: "2026-08-10T20:04:20.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295443352.md)
  - [en](https://longbridge.com/en/news/295443352.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295443352.md)
---

# Damora Q2 net loss widens to $31.17 million

-   Damora posted a GAAP net loss of USD 31.17 million for the quarter ended June 30, 2026, widening from USD 3.44 million a year earlier. \* Operating loss widened to USD 34.99 million from USD 3.42 million, as operating expenses climbed to USD 34.99 million. \* R&D expense rose to USD 25.54 million from USD 1.47 million, while G&A costs increased to USD 9.45 million from USD 1.96 million. \* Other income swung to USD 4.08 million from a loss of USD 12,000, driven by higher interest income following recent financings. \* Damora said it recently initiated a Phase 1/1b trial of lead candidate DMR-001, targeting proof-of-concept readouts starting mid-2027. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Damora Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-342307), on August 10, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [DMRA.US](https://longbridge.com/en/quote/DMRA.US.md)

## Related News & Research

- [Damora Therapeutics posts corporate deck on mutCALR-targeted therapies for myeloproliferative neoplasms](https://longbridge.com/en/news/295448291.md)
- [Analyst Reiterates Buy on Damora Therapeutics, Maintains $45 Price Target on Differentiated Clinical Strategy](https://longbridge.com/en/news/295521208.md)
- [AXSM: 46% revenue growth in 2Q 2026 driven by AUVELITY's Alzheimer's launch and pipeline progress](https://longbridge.com/en/news/295396106.md)
- [Zalaris publishes minutes from extraordinary general meeting](https://longbridge.com/en/news/295536162.md)
- [Edwards Lifesciences CVP TAVR Daniel J. Lippis melepas 619 saham senilai $ 56.966,57](https://longbridge.com/en/news/295581060.md)